Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Aug 4;16(8):e0255581. doi: 10.1371/journal.pone.0255581

Factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15–64 years in Botswana

Mpho Keetile 1,*, Kagiso Ndlovu 2, Gobopamang Letamo 1, Mpho Disang 3, Sanni Yaya 4, Kannan Navaneetham 1
Editor: Frank T Spradley5
PMCID: PMC8336819  PMID: 34347841

Abstract

Background

The most commonly diagnosed cancers among women are breast and cervical cancers, with cervical cancer being a relatively bigger problem in low and middle income countries (LMICs) than breast cancer.

Methods

The main aim of this study was to asses factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15–64 years in Botswana. This study is part of the broad study on Chronic Non-Communicable Diseases in Botswana conducted (NCD survey) in 2016. The NCD survey was conducted across 3 cities and towns, 15 urban villages and 15 rural areas of Botswana. The survey collected information on several NCDs and risk factors including cervical and breast cancer screening. The survey adopted a multistage sampling design and a sample of 1178 participants (males and females) aged 15 years and above was selected in both urban and rural areas of Botswana. For this study, a sub-sample of 813 women aged 15–64 years was selected and included in the analysis. The inequality analysis was conducted using decomposition analysis using ADePT software version 6. Logistic regression models were used to show the association between socioeconomic variables and cervical and breast cancer screening using SPSS version 25. All comparisons were considered statistically significant at 5%.

Results

Overall, 6% and 62% of women reported that they were screened for breast and cervical cancer, respectively. Women in the poorest (AOR = 0.16, 95% CI = 0.06–0.45) and poorer (AOR = 0.37, 95% CI = 0.14–0.96) wealth quintiles were less likely to report cervical cancer screening compared to women in the richest wealth quintile. Similarly, for breast cancer, the odds of screening were found to be low among women in the poorest (AOR = 0.39, 95% CI = 0.06–0.68) and the poorer (AOR = 0.45, 95% CI = 0.13–0.81)) wealth quintiles. Concentration indices (CI) showed that cervical (CI = 0.2443) and breast cancer (CI = 0.3975) screening were more concentrated among women with high SES than women with low SES. Wealth status was observed to be the leading contributor to socioeconomic inequality observed for both cervical and breast cancer screening.

Conclusions

Findings in this study indicate the need for concerted efforts to address the health care needs of the poor in order to reduce cervical and breast cancer screening inequalities.

Introduction

The most commonly diagnosed cancers among women globally are breast and cervical cancers [1], with cervical cancer being a relatively bigger problem in low and middle income countries (LMICs) than breast cancer [2]. It is estimated that globally, more than 2 million women are diagnosed with breast or cervical cancer each year [3]. Of this proportion, approximately 85% of women diagnosed and 88% of women who die from cervical cancer are from LMICs [3]. Several factors are often at play when it comes to prevalence of cervical or breast cancer screening. Literature indicates that whether a woman develops cancers, how early it manifests, whether she has access to safe and affordable diagnostic and treatment services is a function of her place of residence, in which country, in areas remote from health care services, and how she lives—poor or otherwise socially disenfranchised [1].

While cervical cancer risk factors are modifiable, some evidence suggests that breast cancer risk factors are not modifiable or are hard to control at the population level, as a result early detection, as well as proper treatment, is indispensable for improving the disease prognosis [4]. In many countries, particularly LMICs the Papanicolaou (PAP) smear test is the most common strategy employed to reduce cervical cancer incidence and mortality [5]. The three screening methods for breast cancer include breast self-examination (BSE), physical examination of the breasts by a physician or qualified health workers or clinical breast examination (CBE) and mammography (HICs) [5]. Cervical and breast cancers are largely preventable diseases in most HICs due to screening, early detection, and treatment, while in LMICs many women still lack information about these diseases [6]. Similarly there is lack of information about their risk factors, access to screening and early treatment, and oncology services for the treatment of advanced diseases [7].

The Southern Africa region ranked third among regions in cervical cancer deaths in 2012, with an age-standardized rate (ASR) of 17.9 women per 100,000 compared to a worldwide ASR of 6.8 per 100,000 [8]. Since early detection and treatment of cervical and breast cancers play a significant role in determining outcomes for women with cervical or breast cancer, considerable attention has been paid by health professionals and researchers to promote women’s utilization of prevention services in the region. For instance, several studies conducted in South Africa, Zimbabwe and Zambia has shown that there has been a scale-up of screening [9]. Meanwhile several factors have been linked to cancer screening. They include being age, education, insurance, wealth status, culture, income, misconceptions about cervical or breast cancer, and perceived vulnerability to the disease [1012]. Some studies in LMICs have linked low levels of knowledge and uptake of cervical and breast cancer screening to low socio-economic status (SES) [11, 13, 14]. Consequently, inequalities in the use of breast and cervical cancer screening services due to SES have been detected in some settings [11, 12], with more deprived women less likely to be screened. For instance, in Europe a study comparing cervical and breast cancer screening inequalities by educational level found that inequality is not a generalized phenomenon [14].

Botswana like many other LMICS is faced with the increasing cases of cervical and breast cancers. The last two decades have seen remarkable increases in cervical and breast cancer cases. As a result the government came with a response plan which includes cervical cancer screening in the form of cytology [14]. Even at that, access to early screening and early treatment, and oncology services for the treatment of advanced cancer is still a challenge, especially for disadvantaged women. Furthermore, cancer screening programs have had a limited impact on cervical cancer incidence and mortality due to challenges with follow-up, as well as pathological and treatment capacity in a setting where screening results are positive for a high proportion of women [14]. Moreover, while the Ministry of Health and Wellness (MOHW) has recognized the need to substantially improve and support cancer screening in the rising burden of cancers in general, cervical cancers and breast screening inequalities can be reduced.

It has been reported that in Botswana most women only seek medical help in the late stage of the disease [12]. This has been attributed to inadequate knowledge of breast and cervical cancer examination. Few studies have attempted to examine the extent of socioeconomic inequalities in breast and cervical cancer screening among adult women in the context of a universal primary health care setting. Understanding the extent of and examining socioeconomic inequalities in breast and cervical cancer screening among women is vital for the formulation of intervention strategies to reduce morbidity and mortality due to cancer among the disadvantaged women.

Materials and methods

Ethical statement

The study proposal along with the survey instruments were submitted to and approved by the Institutional Review Board of the University of Botswana (Ref #: UBR/RES/IRB/1583) for ethical clearance. Ethical clearance and research permit were also obtained from the Government of Botswana through the Ministry of Health and Wellness (Ref #: HPDME: 13/18/1 Vol. X (130). Informed written consent was sought from all eligible participants before the interviews. Privacy and confidentiality of the highest standard was maintained throughout the study by keeping the respondents anonymous.

Setting

This study is part of the broad study on Chronic Non-Communicable Diseases in Botswana conducted (NCD survey) by Department of Population Studies in 2016. The NCD survey was conducted across 3 cities and towns, 15 urban villages and 15 rural areas of Botswana. The survey collected information on several other NCDs and NCD risk factors which were not covered in the WHO STEPS Botswana Surveys including cervical and breast cancer.

Study design and sampling

The NCD survey used a mmultistage probability sampling design to collect data on various types of NCDs as stated in the ICD-10 classification of NCDs [15]. Four stages of sampling were employed for data collection. First, the census districts were divided into rural and urban clusters. At the second stage, urban districts were divided into cities or towns and urban villages while rural clusters were maintained. Thirdly, a random selection of 3 cities and towns in the cities and towns strata, 15 urban villages from urban villages’ strata and 15 rural villages’ from the rural areas strata was made.

The final and fourth stage was the selection of enumeration areas using probability proportional to size sampling method for the different strata and localities. Then for every selected enumeration area (EA), 20 households were selected using systematic sampling method. This was done based on the guidelines used in most demographic health surveys (DHS) where 20–25 households (HHS) are selected from the primary sampling units (PSUs) [16]. The modified de facto type of enumeration was adopted for the NCD survey, whereby respondents above 15 years old were enumerated at the place where they were found at the time of survey using the interviewer (canvasser) method. At an EA, the coin was tossed to determine the cardinal point where the enumeration would start. The first household to be interviewed was determined using the day code. For instance, on the 29th March 2016 –the first household to be enumerated would be the 7th household from the farthest point of the EA. This code was arrived at by adding the digits 2 and 7. After this procedure, the listing of all eligible respondents aged 15 years and above was done. If there was more than one eligible participant in the selected household, one older person was selected to participate by a lottery method. If the eligible older person was absent during the first data collection visit, the interviewer arranged to return at another time to do the interview.

From an estimated initial sample size of 1280 respondents, a total of 1178 respondents aged 15 years and over who had successfully completed the NCD survey individual questionnaire were interviewed. For this study, a selection of women aged 15–64 years was made using SPSS version 27 data selection command. The inclusion criteria were such that all women who had successfully responded to questions on breast and cervical cancer screening were considered for analysis, while those who did not were excluded from the sample. The final sample size used for this study is 813 women aged 15–64 years.

Measurement of variables

Outcome variables

Cervical cancer screening. This variable was computed from the question “The last time you had the pelvic examination; did you have a PAP smear test?” The resultant variable was such that women who did PAP smear were given a code 1 and 0 if otherwise.

Breast cancer screening. For this variable the question asked was ‘when was the last time you had a mammography, if ever? A code of 1 was given to women who ever once did a mammography and 0 was given to those who never did mammography.

Explanatory variables

Based on literature review [17], variables such as age, marital status, work status, residence, wealth status and education were considered as explanatory variables. Age was categorised into 15–24, 25–34, 35–49 years; marital status as married and not married; residence as urban and rural; and education as primary or lower, secondary and tertiary or higher. Wealth status was created from information on ownership of durable assets collected from respondents during the survey (e. g. ownership of car, refrigerator, and television), housing characteristics (e. g. material of dwelling floor and roof, main cooking fuel), access to basic services (e. g. electricity supply, source of drinking water, sanitation facilities) and ownership of livestock (e.g. cattle, goats, sheep, horses, chickens). The principal component analysis was then used to derive wealth quintiles, which have five categories from the 1st to the 5th quintile (poorest to richest).

Data analysis

Multiple data analyses techniques were employed to assess socioeconomic inequalities in breast and cervical cancer screening. First univariate and bivariate analyses was undertaken to describe the sample and patterns of cervical and breast cancer screening. Second, logistic regression analysis was used to assess the association between socioeconomic variables and cervical and breast cancer screening using SPSS version 27. Results of logistic regression models were presented as adjusted odds ratios (AOR) together with their 95% confidence intervals.

Third, analysis of inequalities in cervical and breast cancer screening was done using ADePT software (version 6). The concentration curves and concentration indices were used to assess inequalities in cervical and breast cancer screening among women. The cumulative shares of the cervical and breast cancer screening variables were plotted using concentration curves against the cumulative share of the wealth status variable. In order to calculate the cumulative percentages, wealth status was ranked from lowest to highest quintile. If cervical or breast cancer screening was equally distributed among women, the curve would be observed running from the bottom left hand corner to the top right-hand corner (a 45° line) which is known as the line of equality. On the other hand, if the share of cervical or breast cancer screening was low among the women of low SES, the concentration curve would lie below the line of equality [18, 19]. The degree of inequality was assessed by the distance of the curve from the line of equality. The further the curve is from this line, the greater the degree of inequality. The first case of socioeconomic inequality is the case in which women with high SES have a positive value of concentration index., while the second case, where the curve is above the diagonal line, is known as socioeconomic inequality which disadvantages the women of lower SES and the value of the concentration index is negative [20].

The value of the cervical and breast cancer screening assigned to each woman was taken to be a function of the socioeconomic category to which the woman belongs. The value of the concentration index ranges between − 1 to + 1. The index is 0 if there is no socioeconomic related inequality. The achievement index was also used with the concentration index to reflect the average level of cervical and breast cancer screening and the inequality in cervical and breast cancer screening between the low SES women and the high SES women. It is the weighted average of cervical and breast cancer screening of the women in the sample, in which higher weights are, attached to low SES women than to high SES women [18]. The larger value of the index is considered as higher health dis-achievement to one group of women than the other group.

Results

Sample description

From a total sample of 813, the highest proportion in the sample constituted women in ages 25–34 years (27.3%) and <24 years, respectively (Table 1). Moreover, the highest proportion of women in the sample were urban village residents (47%), had secondary education (43%), were unemployed (44.8%), never-married (70.2%) and were in the poorer wealth quintile (22.3%). Overall, 62% and 6% of women reported that they were screened for cervical and breast cancer, respectively.

Table 1. Sample description.

Variable N (813) %
Age
<24 190 23.4
25–34 222 27.3
35–44 156 19.2
45–54 124 15.3
55–64 75 9.2
>65 44 5.5
Place of residence
Cities and towns 208 25.6
Urban villages 382 47.0
Rural villages 223 27.3
Education level
Primary or less 335 41.2
Secondary 350 43.0
Tertiary or higher 128 15.8
Work status
Public sector 76 9.3
Private sector 98 12.1
Self-employed 69 8.5
Un-employed 364 44.8
Home-maker/student 153 18.8
Retired/other 53 6.5
Marital status
Never-married 571 70.2
Currently married 149 18.3
Formerly married 93 11.5
Wealth status
Poorest 179 22
Poorer 181 22.3
Middle 166 20.4
Richer 152 18.7
Richest 135 16.6
Breast cancer screening
Yes 49 6.0
No 764 94.0
Cervical cancer screening
Yes 504 62.0
No 309 38.0

Prevalence of cervical and breast cancer screening

Table 2 shows the prevalence of cervical and breast cancer screening among women in the sample. The proportion of women who did cervical cancer screening increased with age until 64 years. For instance, 31% of women aged <24 years were screened for cervical cancer, compared to 71% among women in ages 55–64 years. Cervical cancer screening was also noted to be significantly high among public sector employees (77.2%), currently married (75.3%) and richest women (79.5%). All the comparisons were statistical significant at 5% level.

Table 2. Prevalence of cervical and breast cancer screening among women aged 10–64 years in Botswana, 2016.

  Cervical cancer screening Breast cancer screening
Variable n (%) p-value n (%) p-value
Age   0.00   0.03
<24 21 (31.3) 5 (4.1)
25–34 80 (69.6) 10 (6.9)
35–44 63 (71.6) 6 (5.6)
45–54 55 (78.6) 6 (7.9)
55–64 22 (71.0) 4 (8.7)
>65 5 (29.4) 2 (6.7)
Place of residence   0.51   0.88
Cities and towns 78 (65.0) 11 (6.4)
Urban villages 128 (62.7) 15 (5.4)
Rural villages 60 (57.7) 11 (6.4)
Education level   0.06   0.10
Primary or less 89 (58.6) 10 (4.0)
Secondary 113 (61.4) 16 (6.2)
Tertiary or higher 61 (73.5) 10 (10.0)
Work status   0.00   0.03
Public sector 44 (77.2) 6 (12.8)
Private sector 40 (65.6) 9 (12.2)
Self-employed 26 (72.2) 1 (1.7)
Un-employed 107 (62.6) 14 (5.1)
Home-maker/student 29 (39.7) 5 (3.9)
Retired/other 20 (71.4) 2 (5.9)
Marital status   0.16   0.99
Never-married 174 (59.0) 26 (6.1)
Currently married 67 (75.3) 7 (5.8)
Formerly married 25 (56.8) 4 (5.8)
Wealth status   0.00   0.02
Poorest 39 (43.8) 3 (2.2)
Poorer 48 (57.8) 8 (5.9)
Middle 62 (70.5) 10 (8.1)  
Richer 55 (61.1) 7 (5.6)  
Richest 62 (79.5) 9 (8.9)  

Correlates of breast and cervical cancer screening

Table 3 shows the adjusted odd ratios for the association between cervical and breast cancer screening and socioeconomic characteristics of sampled women. For both cervical and breast cancer screening the odds of being screened significantly increased with age until ages 45–64 years, but declined thereafter. For instance, there were no significant variations in cervical cancer screening for women in ages less than 24 years, and the odds of screening for cervical cancer were 10 times (AOR = 10.1, 95% CI = 2.54–40.6) higher among individuals aged 45–54 years compared to women aged 65 years and above. Similarly the odds of breast cancer screening increased with age and were significantly high among women aged 45–54 years (AOR = 2.61, 95% CI = 1.23–3.64) compared to women aged 65 years and above.

Table 3. The adjusted odds ratios for the association between cervical and breast cancer screening and socioeconomic characteristics of sampled women, 2016.

Cervical cancer screening Breast cancer screening
Variable AOR 95% CI AOR 95% CI
Age        
<24 1.03 (0.22–4.81) 0.22 (0.02–2.06)
25–34 5.62*** (1.28–24.6) 1.23*** (1.06–3.11)
35–44 8.45*** (2.04–35.0) 1.43*** (1.13–3.24)
45–54 10.1*** (2.54–40.6) 2.61*** (1.23–3.64)
55–64 5.61*** (1.32–23.7) 1.07 (0.15–7.46)
>65 1.00   1.00  
Place of residence        
Cities and towns 1.00   1.00  
Urban villages 0.91 (0.49–1.68) 0.63 (0.24–1.67)
Rural villages 0.68 (0.33–1.41) 1.32 (0.44–3.96)
Education level        
Primary or less 0.81 (0.32–2.02) 0.25 (0.06–1.08)
Secondary 1.06 (0.50–2.21) 0.71 (0.24–2.09)
Tertiary or higher 1.00   1.00  
Work status        
Public sector 0.47 (0.12–1.78) 1.49*** (1.12–5.23)
Private sector 0.28 (0.08–1.01) 2.69 (0.47–15.4)
Self-employed 0.36 (0.09–1.42) 0.3 (0.03–3.67)
Un-employed 0.42 (0.13–1.32) 1.09 (0.21–5.62)
Home-maker/student 0.21*** (0.06–0.75) 0.68 (0.10–4.56)
Retired/other 1.00   1.00  
Marital status        
Never-married 0.65 (0.21–1.97) 0.97 (0.20–4.65)
Currently married 0.60 (0.18–1.96) 0.78 (0.15–4.03)
Formerly married 1.00   1.00  
Wealth status        
Poorest 0.16*** (0.06–0.45) 0.39*** (0.06–0.68)
Poorer 0.37*** (0.14–0.96) 0.45*** (0.13–0.81)
Middle 0.51 (0.19–1.34) 1.07 (0.28–4.10)
Richer 0.37 (0.16–1.86) 1.32 (0.36–4.88)
Richest 1.00   1.00  

Note:

*** statistically significant at 5% level.

The odds of cervical cancer screening were significantly low among students and home makers (AOR = 0.21, 95% CI = 0.06–0.75) compared to retired women. Meanwhile, the odds of breast cancer screening were significantly higher among public sector employees (AOR = 1.49, 95% CI = 1.12–5.23) than retired women. Women in the poorest (AOR = 0.16, 95% CI = 0.06–0.45) and poorer (AOR = 0.37, 95% CI = 0.14–0.96) wealth quintiles were less likely to report cervical cancer screening compared to women in the richest wealth quintile. Similarly, for breast cancer, the odds of screening were found to be low among women in the poorest (AOR = 0.39, 95% CI = 0.06–0.68) and the poorer (AOR = 0.45, 95% CI = 0.13–0.81)) wealth quintiles. There were no statistically significant educational, residential and marital status variations in cervical and breast cancer screening among women.

Inequalities in cervical and breast cancer screening

Table 4 below presents the results of the inequality measures of concentration indices (CI) and the standard achievement indices for cervical and breast cancer screening. In a scenario where the concentration index is high, the achievement index is expected to be low and vice versa [19]. The positive CI value of 0.2443 for cervical cancer screening shows that the inequality is skewed towards women of high SES and the corresponding standard achievement index is low. Similarly the positive CI value of 0.3975 indicates that breast cancer screening is concentrated among women of high SES. The positive CI value for breast cancer screening is also accompanied by low corresponding standard achievement index.

Table 4. Concentration indices showing inequalities in cervical and breast cancer screening in Botswana, (2016).

Variable  Concentration Index (CI) 95% Confidence intervals for CI Standard achievement index
Cervical cancer screening 0.2443 (0.1003,0.4150) 0.1224
Breast cancer screening 0.3975 (0.1242–6.131) 0.1442

The concentration curves plotting the cumulative share of cervical and breast cancer screening variables against the proportional cumulative share of wealth index (SES) score of women are shown in Fig 1. The curve for both cervical and breast cancer screening lie below the line of equality which confirms that cervical and breast cancer screening was more concentrated among women of high SES. Meanwhile, the concentration curve for breast cancer screening is the furthest from the line of equality indicating that screening for breast cancer was slightly more concentrated among the women of high SES compared to cervical cancer screening. However, the inequality for both variables is significantly high.

Fig 1. Concentration curves for cervical and breast cancer screening-NCD survey, 2016.

Fig 1

Decomposing inequalities in cervical and breast cancer screening

The decomposition of the concentration indices for cervical and breast cancer screening are shown in Table 5. These CIs explain why inequalities in cervical and breast cancer screening exist and what factors contribute to these observed inequalities. The results of decomposition show that variables such as residence, age and marital status had negative contribution to the inequalities for cervical and breast cancer screening. On the other hand, education, work status and wealth status itself dominated in the decomposition of the large concentration index for cervical and breast cancer screening. This was indicated by positive coefficients for these variables.

Table 5. Decomposition of the concentration indices of the covariates for cervical and breast cancer screening variables.

  Cervical cancer screening Breast cancer screening
Covariates  coefficient coefficient
Residence -0.2769 -0.2352
Age -0.0528 -0.0523
Education 0.1099 0.1031
Marital status -0.0088 0.1276
Work status 0.0256 0.0268
Control variables  
Wealth Index 1.6420 3.0863

Discussion

This study examined factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15–64 years in Botswana. It emerged that majority of women had done cervical cancer screening than breast cancer screening. This is consistent with findings in many LMICs which have generally shown that cervical cancer is the second most common cancer in women in low- and middle-income countries (LMICs) [2123]. Consequently screening rates for this type of cancer among women is comparatively high. This is mainly because in recent years, cervical cancer screening recommendations have relatively been updated and received more attention compared to mammography in Botswana.

The odds of being screened for cervical cancer were found to significantly increase with the age of women and were highest in ages 45–54 years, but declined thereafter. This finding is consistent with other previous studies which found that cervical cancer infection rates in women have generally been observed to peak in the years after sexual debut [2426]. Consequently majority of women in these ages are more liable to screen for cervical cancer compared to women of younger ages. The American Cancer Society (ACS) recommends that women should undergo cervical cancer screening at age 25 years and undergo primary human papillomavirus (HPV) testing every 5 years through age 65 years (preferred); if primary HPV testing is not available, then women aged 25 to 65 years should be screened with co-testing (HPV testing in combination with cytology) every 5 years or cytology alone every 3 years [27].

Similarly the odds of breast cancer screening were found to increase with age of women but were highest in ages 45–54 years. This corroborates previous studies which have shown that women aged 40 years and above are at a greater risk of developing breast cancer [2628]. Consequently they should under routine mammography, to enhance early detection of breast cancer. Although there are conflicting guidelines on the appropriate age for continuous breast cancer screening, the general consensus is that breast cancer screening intervals of 1–3 years for women aged 25–39 and annually for women aged 40 years and older are reasonable [28]. This offers a plausible explanation for high breast cancer screening rates among women aged 45–54 years in Botswana.

Consistent with previous studies [24, 26, 2830], we found that women of low SES were found to be less likely to report both breast and cervical cancer screening compared to women of high SES. This is mainly because women from disadvantaged households are less likely to be knowledgeable and therefore unlikely to screen for cervical and breast cancer. This re-emphasizes the notion that those who have the financial means overcome barriers to accessing care compared to those who are poor. Unlike women of high SES, women of low SES do not have access to information and do not have access to insurance coverage. As a result providing health insurance to poor women may remove or reduce these financial barriers and guarantee a certain degree of equity in the use of cancer and breast screening services. Moreover, providing insurance to low SES women will give them the option to use private health facilities instead of few cervical and breast cancer screening public health facilities. Furthermore, the public health facilities are often congested and bookings for screening are delayed which is a major disadvantage to women of low SES who may require urgent screening. On the other hand there were no statistically significant educational, residential and marital status variations in cervical and breast cancer screening among women.

Inequalities in breast and cervical cancer screening among women were observed in Botswana despite the country-wide effort to improve the socioeconomic status and primary healthcare coverage of the population. The decomposition analysis shows that wealth status seems to be an important positive contributor to the concentration indices of the cervical and breast cancer screening outcomes. This means inequality in wealth makes cervical and breast cancer screening more predominant among richer individuals. Low uptake and disparities in cancer screenings could be attributed to the low level of awareness about the importance of early screening, which places a high proportion of low SES women under the risk of late detection.

Study limitation

Certain limitations are worth mentioning. First, the cross-sectional nature of the data does not allow drawing causal inferences. Secondly, the NCD study sample was not designed to be representative of Botswana, a caution should be taken while generalizing these study findings.

Supporting information

S1 File

(DOCX)

Data Availability

The data underlying the results presented in the study are available from the Department of Population Studies Data Repository, University of Botswana.Contact; Dr Enock Ngome (Head of Department) Email:ngome@ub.ac.bw Telephone:+267 3552710

Funding Statement

This study was funded by the Office of Research and Development (ORD) at the University of Botswana and any request for data access may be sent to the ORD.

References

  • 1.Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017. Feb 25;389(10071):847–860. doi: 10.1016/S0140-6736(16)31392-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015. Aug 22; 386(9995):743–800. doi: 10.1016/S0140-6736(15)60692-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015. Mar 1; 136(5):E359–86. doi: 10.1002/ijc.29210 [DOI] [PubMed] [Google Scholar]
  • 4.Palència L, Espelt A, Rodríguez-Sanz M, Puigpinós R, et al., Socio-economic inequalities in breast and cervical cancer screening practices in Europe: influence of the type of screening program, International Journal of Epidemiology, Volume 39, Issue 3, June 2010; 757–765, doi: 10.1093/ije/dyq003 [DOI] [PubMed] [Google Scholar]
  • 5.World Health Organization. Cervical cancer, human papillomavirus (HPV), and HPV vaccines–Key points for policy-makers and health professionals. World Health Organization, 2007. http://www.who.int [Google Scholar]
  • 6.Hakama M, Coleman MP, Alexe DM, Auvinen A. Cancer screening: evidence and practice in Europe, Eur J Cancer, 2008, vol. 44 (pg. 1404–13) doi: 10.1016/j.ejca.2008.02.013 [DOI] [PubMed] [Google Scholar]
  • 7.Chidyaonga-Maseko F, Chirwa ML, Muula AS. Underutilization of cervical cancer prevention services in low and middle income countries: a review of contributing factors. Pan Afr Med J. 2015; 21(1). doi: 10.11604/pamj.2015.21.231.6350 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.GLOBOCAN. Cancer incidence and mortality worldwide: IARC CancerBase no. 11 [internet]. Lyon: International Agency for Research on Cancer 2012 v1.2,; 2013. Accessed at http://gco.iarc.fr.
  • 9.Barchi F., Winter S.C., Ketshogile F.M. et al. Adherence to screening appointments in a cervical cancer clinic serving HIV-positive women in Botswana. BMC Public Health 19, 318 (2019). doi: 10.1186/s12889-019-6638-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lambert CL. Factors influencing cervical cancer screening in women infected with HIV: a review of the literature. J Assoc Nurses AIDS Care. 2013;24(3):189–97. doi: 10.1016/j.jana.2012.06.010 [DOI] [PubMed] [Google Scholar]
  • 11.Ackerson K, Gretebeck K. Factors influencing cancer screening practices of underserved women. J Am Assn Nurse Pract. 2007;19(11):591–601. doi: 10.1111/j.1745-7599.2007.00268.x [DOI] [PubMed] [Google Scholar]
  • 12.McFarland DM. Cervical cancer and pap smear screening in Botswana: knowledge and perceptions. Int Nurs Rev. 2003;50(3):167–75. doi: 10.1046/j.1466-7657.2003.00195.x [DOI] [PubMed] [Google Scholar]
  • 13.African Pathologists’ Summit Working Groups. Proceedings of the African Pathologists Summit; March 22–23, 2013; Dakar, Senegal: a summary. Arch Pathol Lab Med (2015) 139(1):126–32.10.5858/arpa.2013-0732-CC doi: 10.5858/arpa.2013-0732-CC [DOI] [PubMed] [Google Scholar]
  • 14.Grover S, Raesima M, Bvochora-Nsingo M, et al. Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs. Front Oncol. 2015;5:239. Published 2015 Nov 3. doi: 10.3389/fonc.2015.00239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.World Health Organization. Global status report on non-communicable diseases 2014.Geneva.2014. https://www.who.int/nmh/publications/ncd-status-report-2014/en/
  • 16.World Health Organization, Chronic Disease Risk Factor Surveillance, Botswana STEPs survey. Government Printers. Gaborone.2008
  • 17.Yi S., Tuot S., Chhoun P., Pal K., Tith K., Brody C., et al. Factors associated with inconsistent condom use among men who have sex with men in Cambodia. PloS One, 2015.10(8), e0136114. doi: 10.1371/journal.pone.0136114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wagstaff A, Bilge M, Sajaia Z, Lokshin M. Health equity and financial protection:streamlined analysis with ADePT software. Washington DC: World Bank; 2011. [Google Scholar]
  • 19.Wagstaff A, Van Doorslaer E. Catastrophe and impoverishment in paying for health care: with applications to Vietnam 1993–1998. Health Econ. 2002;12(11):921–34. [DOI] [PubMed] [Google Scholar]
  • 20.Regidor E. Measures of health inequalities: part 2. J Epidemiol Community Health. 2004;58:900–3. doi: 10.1136/jech.2004.023036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Grover S, Raesima M, Bvochora-Nsingo M, et al. Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs. Front Oncol. 2015; 5:239. 2015 Nov 3. doi: 10.3389/fonc.2015.00239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.LaVigne AW, Triedman SA, Randall TC, Trimble EL, Viswanathan AN. Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery. Gynecol Oncol Rep. 2017;22:16–20. doi: 10.1016/j.gore.2017.08.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hull R, Mbele M, Makhafola T, et al. Cervical cancer in low and middle-income countries. Oncol Lett. 2020;20(3):2058–2074. doi: 10.3892/ol.2020.11754 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Smith JS, Melendy A, Rana RK, Pimenta JM Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health. 2008. Oct; 43(4 Suppl):S5–25, S25.e1-41. doi: 10.1016/j.jadohealth.2008.07.009 [DOI] [PubMed] [Google Scholar]
  • 25.Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. Prev Med. 2019; 123: 316‐ 323 doi: 10.1016/j.ypmed.2019.04.010 [DOI] [PubMed] [Google Scholar]
  • 26.Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for cervical cancer with high‐risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018; 320: 687‐ 705 doi: 10.1001/jama.2018.10400 [DOI] [PubMed] [Google Scholar]
  • 27.Fontham ETH,. Wolf AMD, Church TR, Etzioni R, Flowers CR, MD, Herzig A et al., Cervical Cancer Screening for Individuals at Average Risk: 2020 Guideline Update from the American Cancer Society. CA CANCER J CLIN 2020;70:321–346 doi: 10.3322/caac.21628 [DOI] [PubMed] [Google Scholar]
  • 28.The American College of Obstetricians and Gynecologists.Breast Cancer Risk Assessment and Screening in avarage-risk women.Practice Bulletin No. 179,2019.1–16.
  • 29.Kangmennaanga J, Onyangoa EO, Luginaah I, Ellio SJ, The next Sub Saharan African epidemic? A case study of the determinants of cervical cancer knowledge and screening in Kenya. Social Science & Medicine 197 (2018) 203–212. [DOI] [PubMed] [Google Scholar]
  • 30.Al Rifai R.H, Nakamura K, Differences in Breast and Cervical Cancer Screening Rates in Jordan among Women from Different Socioeconomic Strata: Analysis of the 2012 Population-Based Household Survey. Asian Pacific Journal of Cancer Prevention, Vol 16, 2015. doi: 10.7314/apjcp.2015.16.15.6697 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Frank T Spradley

10 Feb 2021

PONE-D-20-39250

Factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15-64 years in Botswana

PLOS ONE

Dear Dr. Keetile,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

An expert in the field handled your manuscript, and we are appreciative of their time and contributions. Although interest was found in your study, some major comments arose during review. Please address ALL of the reviewer's comments in your revised manuscript.

Please submit your revised manuscript by Mar 20 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3.Thank you for stating the following financial disclosure:

"NO"

At this time, please address the following queries:

  1. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

  2. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

  3. If any authors received a salary from any of your funders, please state which authors and which funders.

  4. If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

5.Thank you for submitting the above manuscript to PLOS ONE. During our internal evaluation of the manuscript, we found significant text overlap between your submission and the following previously published works, some of which you are an author.

- https://doi.org/10.1186/s12889-019-7405-x

- https://doi.org/10.1016/j.socscimed.2017.12.013

- https://doi.org/10.7314/APJCP.2015.16.15.6697

We would like to make you aware that copying extracts from previous publications, especially outside the methods section, word-for-word is unacceptable. In addition, the reproduction of text from published reports has implications for the copyright that may apply to the publications.

Please revise the manuscript to rephrase the duplicated text, cite your sources, and provide details as to how the current manuscript advances on previous work. Please note that further consideration is dependent on the submission of a manuscript that addresses these concerns about the overlap in text with published work.

We will carefully review your manuscript upon resubmission, so please ensure that your revision is thorough.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The data seems to have been made to fit a pre-determined conclusion i.e. that socioeconomic inequalities will exist in screening outcomes. This is intuitive and expected. The paper can be strengthened by thinking through the structural inequalities that exist underlying these differences in screening practices. i.e why do women with lower socioeconomic means have lower screening uptake? What can be causing this difference? What is the availability of cancer screening services? Could it be that there is no facility within a certain geographical radius? The structures underlying the distribution of inequality for the populations examined is not explored well.

In essence, the finding that these differences exist are no surprise since this topic has been studied repeatedly in many different countries. What can add to the literature is an examination of WHAT is driving these in the context of Botswana. Some clear next steps can then also be derived which are currently missing from the paper. The authors draw on other literature to cite a lack of awareness or lack of health insurance. But these can be applied more directly to the data for more substantive next steps.

Would also advise the author to keep consistent with use of language. Terms commonly used in the literature are social disadvantage, and how the authors then use this term should be clearly defined. The authors use different language such as poor and wealthy intermixed with disadvantaged.

In the introduction the authors mention the 'problem'. This problem needs to be explained more clearly and tied to the paper more directly.

The authors mention that Pap smears can reduce cervical cancer incidence, this is factually incorrect as Pap smears promote early detection.

Typo with mammography which is abbreviated as HIC in the manuscript.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Aug 4;16(8):e0255581. doi: 10.1371/journal.pone.0255581.r002

Author response to Decision Letter 0


19 May 2021

Response to reviewer’s comments

Comment

Reviewer #1: The data seems to have been made to fit a pre-determined conclusion i.e. that socioeconomic inequalities will exist in screening outcomes. This is intuitive and expected.

Response

Thank you for the comment. Kindly note that this study was derived from the secondary analysis of data for a study conducted by Department of Population Studies at University of Botswana, Faculty of Social Sciences, University of Botswana. The study proposal along with the necessary documents was submitted to and approved by the Institutional Review Board of the University of Botswana (Ref #: UBR/RES/IRB/1583) and the Ministry of Health and Wellness (Ref #: HPDME: 13/18/1 Vol. X (130)) therefore we did not make the data to fit any pre-determined conclusion. Although it may be true that inequalities may exist for the two outcomes, the extent of such inequalities is not known and in Botswana as far as we are concerned this is the first study to assess socioeconomic related inequalities in the context of a universal primary care setting.

Comment

The paper can be strengthened by thinking through the structural inequalities that exist underlying these differences in screening practices. i.e why do women with lower socioeconomic means have lower screening uptake? What can be causing this difference? What is the availability of cancer screening services? Could it be that there is no facility within a certain geographical radius? The structures underlying the distribution of inequality for the populations examined are not explored well.

Response

Thank you so much. This is a valuable comment. We have indicated in the discussion the plausible explanation for observed inequalities. However kindly note that we cannot make causal inference from the cross-sectional data. The dataset did not have any structural variables, which could allow us to explore structural inequalities for breast and cervical cancer screening. However, we have discussed the plausible explanations for observed inequalities, including structural factors. This points the need for a broader study which can explore structural variables.

Comment

In essence, the findings that these differences exist are no surprise since this topic has been studied repeatedly in many different countries. What can add to the literature is an examination of WHAT is driving these in the context of Botswana. Some clear next steps can then also be derived which are currently missing from the paper. The authors draw on other literature to cite a lack of awareness or lack of health insurance. But these can be applied more directly to the data for more substantive next steps.

Response

Although we agree with the reviewers that socioeconomic inequalities for various outcomes are known in most countries, it is not the case in Botswana. Botswana is unique in the sense of universal health care coverage. Moreover, this is the first study to study inequalities, and as far as we are concerned it provides baseline evidence, especially on the extent of inequalities for the two outcomes. This is mainly because cervical and breast cancer screening is done for free in public health facilities. In the background we have also provided the context of why we think this study is credible, especially in Botswana

Comment

Would also advise the author to keep consistent with use of language. Terms commonly used in the literature are social disadvantage, and how the authors then use this term should be clearly defined. The authors use different language such as poor and wealthy intermixed with disadvantaged.

Response

We have checked the language throughout the article and have corrected as per the reviewer’s comment. Kindly note that we have used the term socioeconomic inequality to refer to unjust socioeconomic differences in access and utilization of cervical and breast cancer screening. Previous studies have used the term socioeconomic inequality as used in the context of our study.

Comment

In the introduction the authors mention the 'problem'. This problem needs to be explained more clearly and tied to the paper more directly.

Response

We have made efforts to make the ‘problem’ clearer. We indicate quite clearly that given the context of Botswana inequalities in cervical and breast cancer screening are not expected. As a result this study serves to provide initial evidence on the extent of inequalities in screening.

Comment

The authors mention that Pap smears can reduce cervical cancer incidence, this is factually incorrect as Pap smears promote early detection.

Response

Thank you for the comment; we have duly corrected the statement

Comment

Typo with mammography which is abbreviated as HIC in the manuscript.

Response

Thank you we have made the observed correction

Decision Letter 1

Frank T Spradley

14 Jun 2021

PONE-D-20-39250R1

Factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15-64 years in Botswana

PLOS ONE

Dear Dr. Keetile,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 29 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for addressing the previous comments. The context of the study is now better understood. I still have some concerns around the use of language specifically. Given that the paper is describing socioeconomic inequalities, and that there is an abundance of critical literature that has contextualised this phenomenon, the authors must situate their paper in this body of work – and therefore most of my comments are related to how the authors describe their findings and position their work.

1. Labelling women as poor and wealthy detracts from the conditions leading to socioeconomic inequalities. It is better to use terms such as women living in marginalizing conditions, or women living in poverty. The term ‘poor’ women is used through out the paper and really should be avoided as it a non-critical label that otherizes.

2. In the introduction, authors mention that inequalities are inevitable – however, much contextual understanding now exists around cancer screening and the cancer care continuum which demonstrates that inequalities are indeed avoidable, unjust and unfair and that with the correct allocation of resources these inequalities can be reduced.

Finally, in the discussion the authors mention that health insurance can reduce financial barriers to screening – however, earlier in the paper it is mentioned that cancer screening in Botswana is a public health program provided at no cost to citizens. Please explain.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Ambreen Sayani

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Aug 4;16(8):e0255581. doi: 10.1371/journal.pone.0255581.r004

Author response to Decision Letter 1


16 Jul 2021

Response to reviewers comments-

Comment

Reviewer #1: Thank you for addressing the previous comments. The context of the study is now better understood. I still have some concerns around the use of language specifically. Given that the paper is describing socioeconomic inequalities, and that there is an abundance of critical literature that has contextualised this phenomenon, the authors must situate their paper in this body of work – and therefore most of my comments are related to how the authors describe their findings and position their work.

Response

Thank you so much for your invaluable comments. We appreciate that now you understand the context of our study. We have also made adjustment to our paper based on the local context as suggested by the reviewer.

Comment

Labelling women as poor and wealthy detracts from the conditions leading to socioeconomic inequalities. It is better to use terms such as women living in marginalizing conditions, or women living in poverty. The term ‘poor’ women is used throughout the paper and really should be avoided as it a non-critical label that otherizes.

Response

Instead of using the word poor we have replaced it with low wealth/socioeconomic status as suggested. This is because wealth status variable was used a key dependent variable for measuring inequalities. Our understanding is that wealth status is a documented measure of socioeconomic status hence why we chose to use the word low socioeconomic status to refer to poor wealth status and vice versa.

Comment

In the introduction, authors mention that inequalities are inevitable – however, much contextual understanding now exists around cancer screening and the cancer care continuum which demonstrates that inequalities are indeed avoidable, unjust and unfair and that with the correct allocation of resources these inequalities can be reduced.

Response

We have removed the statement that suggests that inequalities are inevitable but we emphasise that inequalities in cancer screening can be reduced.

Comment

Finally, in the discussion the authors mention that health insurance can reduce financial barriers to screening – however, earlier in the paper it is mentioned that cancer screening in Botswana is a public health program provided at no cost to citizens. Please explain.

Response

Although cervical and breast cancer screening is offered in public facilities , there are few specialised health facilities offering both breast and cervical cancer screening services, meaning that a high proportion of women especially in rural areas have limited access because the bookings for screening services can take as long as 6 months. Consequently this population group are disadvantaged compared to individuals who are on private medical insurance, who have the option to access screening services in private health facilities, which are often more apt. The delay experienced in screening women in public facilities due to limited human resource provides a challenge to low SES women. Our argument on providing medical insurance to poor women is derived from that background.

Decision Letter 2

Frank T Spradley

21 Jul 2021

Factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15-64 years in Botswana

PONE-D-20-39250R2

Dear Dr. Keetile,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Acceptance letter

Frank T Spradley

26 Jul 2021

PONE-D-20-39250R2

Factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15-64 years in Botswana

Dear Dr. Keetile:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Frank T. Spradley

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File

    (DOCX)

    Data Availability Statement

    The data underlying the results presented in the study are available from the Department of Population Studies Data Repository, University of Botswana.Contact; Dr Enock Ngome (Head of Department) Email:ngome@ub.ac.bw Telephone:+267 3552710


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES